Wednesday, 04 November 2021 07:40

£4.45m for University of Glasgow Diabetes spin-out

A spin-out company from the Universities of Glasgow and Southern Denmark has received a £4.45million “Series A” investment from an early stage life science venture capital fund.

Caldan Therapeutics is developing drugs targeting the free fatty acid receptors for Type 2 Diabetes, and has secured the funding from organisations including Epidarex Capital and the Scottish Investment Bank.

The company arose from a long-term collaboration between the University of Southern Denmark’s Professor Trond Ulven and Professor Graeme Milligan of the University of Glasgow.

Caldan focuses on creating therapeutics that activate free fatty acid receptors, in order to deliver anti-diabetic effects in tissues and organs, which would provide a “step change” in the treatment of T2D.

Professor Milligan, professor of Molecular Pharmacology and Gardiner Chair of Biochemistry, said: “We’re very pleased that Caldan is receiving the backing of Epidarex Capital and their partners. The underpinning basic science studies that have pointed the way to assess this new type of treatment for T2D has been a true multidisciplinary collaboration between researchers here in Glasgow and our partners in Denmark. Our combined knowledge has led us to develop approaches we would never have created individually.”

Professor Ulven, head of research for Medicinal Chemistry and Pharmaceutical Technology, said: “Combined, we believe our approach towards these receptors could do what T2D patients need. We have built up insight into these receptors over the last few years, and are equipped to potentially generate safe and efficacious compounds with the right properties.”

Elizabeth Roper, partner at Epidarex Capital, added: “Caldan provides an opportunity for Epidarex to back two leading scientific founders in the T2D space with some exciting new approaches.”

  • Facebook Page: 165971433539526
  • Twitter: SBNNAberdeen
  • YouTube: aberdeenbusiness

Scottish Business News Network (SBNN)
111 Gallowgate
AB25 1BU

T - 01224 619751

E - This email address is being protected from spambots. You need JavaScript enabled to view it.